Global Stem Cell Banking Market Outlook to 2028

The report provides a comprehensive analysis of the potential of Global Stem Cell Banking Market. The report covers an overview and genesis of the industry, market size in terms of revenue generated.

The report has market segmentation which include segments by source, by service type, by application, by cell type and by region; growth enablers and drivers; challenges and bottlenecks; trends driving adoption trends; regulatory framework; end-user analysis, industry analysis, competitive landscape including competition scenario and market shares of major players. The report concludes with future market projections of each market segmentation and analyst recommendations.

Market Overview:

According to publisher estimates, the Market Size of Global Stem Cell Banking has shown increasing trend from 2017 to 2022. However, due to COVID-19 restrictions and national & international guidelines, additional measures were taken to ensure secure stem cells collection from patients as well as donors, which resulted in decline in the overall stem cell banking market.

• Placental stem cells are expected to dominate the global stem cell banking market by source due to high immune tolerance which make them a promising option for transplantation and other therapeutic applications
• The major market players are focusing on R&D activities to introduce new stem cell therapies in the market

Key Trends by Market Segment:

• By Source: Placental stem cells are a most common source of stem cells because they offer several advantages over other sources
• By Service Type: Sample collection and transportation is one of the most common types of services offered by stem cell banks because it is the first and most critical part of the process of preserving stem cells for future use

Future Outlook:

Market Size of Global Stem Cell Banking is expected to show increasing trend from 2022 to 2027. This is owing to increase in R&D due to therapeutic purpose, advancement in regenerative medicines, rising investment for stem cell therapy and banking and ability to test new drugs for safety and effectiveness.